ReviewReviews in medical virology2022
Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities.
Review in Reviews in medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Genomic Variant Surveillance of SARS-CoV-2 Positive Specimens Using a Direct PCR Product Sequencing Surveillance (DPPSS) Method.Acta medica Philippina · 2026Article
- Low Uptake and Disparities in Respiratory Syncytial Virus Vaccination Among US Veterans.Open forum infectious diseases · 2025Article
- A Case ofJournal of general and family medicine · 2025Article
- Review
- A Study of Transplacental Transfer of SARS-CoV-2 Antibodies in COVID-19 Vaccinated Women in Mumbai, India.Cureus · 2025Article
- 2025 Expert Consensus Recommendations on Vaccinations in Adults with High Cardiovascular Risk and Cardiovascular Disease: A Report of the Task Force of the Taiwan Society of Cardiology and the Infectious Diseases Society of Taiwan.Acta Cardiologica Sinica · 2025Article
- New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.Enfermedades infecciosas y microbiologia clinica · 2025Review
- Managing Silicosis in the United States: How I Do It.CHEST pulmonary · 2024Article
- Delphi Panel Consensus Statement Generation: COVID-19 Vaccination Recommendations for Immunocompromised Populations in the European Union.Infectious diseases and therapy · 2024Article
- Hesitation towards COVID-19 booster vaccination among dialysis patients: a cross-sectional study in Taizhou, China.BMC infectious diseases · 2024Article
- Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.European journal of clinical pharmacology · 2024Article
- Article
- COV2Var, a function annotation database of SARS-CoV-2 genetic variation.Nucleic acids research · 2024Article
- Adverse events following COVID-19 vaccination: A comprehensive analysis of spontaneous reporting data in Ghana.PLOS global public health · 2024Article
- The protection of CoronaVac against the infection of wild-type SARS-CoV-2 (WH-09) or Omicron variant in nude-hACE2 mice.Animal models and experimental medicine · 2023Article
- Pediatric COVID-19 and Diabetes: An Investigation into the Intersection of Two Pandemics.Diagnostics (Basel, Switzerland) · 2023Review
- SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19.Diagnostics (Basel, Switzerland) · 2023Review
- COVID-19 in children and adolescents with neuroimmunological disorders.Clinics (Sao Paulo, Brazil) · 2023Article
- COVID-19 vaccine coverage, safety, and perceptions among patients with diabetes mellitus in China: a cross-sectional study.Frontiers in endocrinology · 2023Article
- A semi-quantitative upconversion nanoparticle-based immunochromatographic assay for SARS-CoV-2 antigen detection.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid-19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid-19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end-stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.